Here we provide a selection of scientific publications related to IOZK immunotherapy. You can use the filters to make a selection according to tumor types and methods, or enter search terms.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-03-07 / Ann. Hematol. 2006 May;85(5):308-14https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-03-07 / Ann. Hematol. 2006 May;85(5):308-142006-03-07 00:00:002019-02-15 09:25:36Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin’s lymphoma and multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-28 / AIDS 2006 Feb;20(4):627-30https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-28 / AIDS 2006 Feb;20(4):627-302006-02-28 00:00:002019-02-15 09:15:17Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-04 / Cancer Immunol. Immunother. 2006 Nov;55(11):1309-19https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-04 / Cancer Immunol. Immunother. 2006 Nov;55(11):1309-192006-02-04 00:00:002019-02-15 08:59:59Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-01 / Leuk. Lymphoma 2006 Feb;47(2):297-306https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-01 / Leuk. Lymphoma 2006 Feb;47(2):297-3062006-02-01 00:00:002019-02-15 08:37:31Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-01 / HBPD INT 2006 Feb;5(1):22-7https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-01 / HBPD INT 2006 Feb;5(1):22-72006-02-01 00:00:002019-02-15 09:17:43Recent advances in heat shock protein-based cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-672006-02-01 00:00:002020-06-23 09:36:57A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-87https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-872006-02-01 00:00:002019-02-15 08:48:35Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation
Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin’s lymphoma and multiple myeloma
Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice
Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses
Combined action of virus injection and local tumor irradiation on tumor growth in mice
Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells
Hyperthermia enhances CTL cross-priming
Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA
Therapeutic cancer vaccines
Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12
Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation
Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost
Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate
Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens
Novel immunotherapeutic approaches to glioma
Recent advances in heat shock protein-based cancer vaccines
A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer